Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype

Journal of the American College of Cardiology

Volumn 38, Issue 7, 2001, Pages 1799-1805

  Pullin, Catherine H ^a   Ashfield Watt, Pauline A L ^a   Burr, Michael L ^a   Clark, Zoë E ^a   Lewis, Malcolm J ^a   Moat, Stuart J ^b   Newcombe, Robert G ^a   Powers, Hilary J ^b   Whiting, Jenny M ^a   McDowell, Ian F W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; PLACEBO; VON WILLEBRAND FACTOR;

ADULT; ARTERY DIAMETER; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEMODYNAMIC PARAMETERS; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NUTRITIONAL REQUIREMENTS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; REFERENCE VALUES; VASCULAR RESISTANCE;

EID: 0035195610     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01668-0     Document Type: Article

References (35)

1. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease
2. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies
3. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
4. Lowering blood homocysteine with folic acid-based supplements: Meta-analysis of randomised trials
5. Relationship between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
6. Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology
7. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
8. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia
9. Genes, greens, and homocysteine
10. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomomcysteinemia but not to vascular disease: The results of a meta-analysis
11. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects
12. Putative mechanisms for vascular damage by homocysteine
13. Impaired endothelium-dependent vasodilatation of large epicardial and resistance coronary arteries in patients with essential hypertension: Different responses to acetylcholine and substance P
14. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelial-dependent dilation in healthy young adults
15. Impaired endothelium-dependent vasodilatation in patients with insulin-dependent diabetes mellitus
16. The endothelium in atherothrombotic disease: What can the laboratory tell us?
17. Impaired endothelial function occurs in systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents
18. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans
19. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans
20. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
21. Endothelial control of arterial distensibility is impaired in chronic heart failure
22. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project
23. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes
24. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia
25. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults
26. Acute hyperhomocysteinaemia and endothelial dysfunction
27. 12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia
28. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid
29. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia
30. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolaemia
31. Folic acid reverts dysfunction of endothelial nitric oxide synthase
32. Endothelium-dependent flow-mediated vasodilatation in coronary and brachial arteries in suspected coronary artery disease
33. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
34. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfuncfion
35. 6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease